THERAPY DOSSIER · th-9c5693577072

(+)-Clausenamide ((+)-CLA)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Preclinical/no trial
ChEMBL record: CHEMBL508970 ↗
ChEMBL max phase: Not recorded
Synonyms: (+)-Clausenamide
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32951003 ↗2020Reported benefit

(+)-Clausenamide protects against drug-induced liver injury by inhibiting hepatocyte ferroptosis

MouseChemical/toxinC57BL/6MaleIntragastric (oral gavage)50 mg/kg/day (also tested up to 100 mg/kg/day), intragastri…Pretreatment for 7 consecutive days before the APAP or erastin challenge

Model: Acetaminophen (APAP)-induced or erastin-induced drug-induced liver injury

(+)-CLA significantly improved liver function and histopathology, reduced hepatocyte death, reversed GSH depletion, and inhibited lipid peroxidation in both APAP- and erastin-induced liver injury models; mechanistically, (+)-CLA restored GPX4 and SLC7A11 levels, indicating inhibition of ferroptosis…

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…